Debrisoquin sulfate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317584

CAS#: 581-88-4 (sulfate)

Description: Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.


Chemical Structure

img
Debrisoquin sulfate
CAS# 581-88-4 (sulfate)

Theoretical Analysis

MedKoo Cat#: 317584
Name: Debrisoquin sulfate
CAS#: 581-88-4 (sulfate)
Chemical Formula: C20H28N6O4S
Exact Mass: 175.11
Molecular Weight: 448.542
Elemental Analysis: C, 53.56; H, 6.29; N, 18.74; O, 14.27; S, 7.15

Price and Availability

Size Price Availability Quantity
100mg USD 350
200mg USD 550
500mg USD 1150
Bulk inquiry

Related CAS #: 581-88-4 (sulfate)   1131-64-2 (free base)   1131-65-3 (HBr)   1131-66-4 (HCl)    

Synonym: Debrisoquine; Debrisoquin; Debrisochinum; Isocaramidine; Tendor; Debrisoquina; Debrisoquin sulfate

IUPAC/Chemical Name: 3,4-dihydro-1H-isoquinoline-2-carboximidamide; sulfate (2:1)

InChi Key: CAYGYVYWRIHZCQ-UHFFFAOYSA-N

InChi Code: InChI=1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)

SMILES Code: N=C(N1CC2=C(C=CC=C2)CC1)N.N=C(N3CC4=C(C=CC=C4)CC3)N.O=S(O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 448.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Maas JW, Contreras SA, Seleshi E, Bowden CL. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin. Arch Gen Psychiatry. 1988 Jun;45(6):553-9. doi: 10.1001/archpsyc.1988.01800300049005. PMID: 3377641.


2: Sternberg DE, Heninger GR, Roth RH. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Life Sci. 1983 May 23;32(21):2447-52. doi: 10.1016/0024-3205(83)90370-3. PMID: 6855448.


3: Riddle MA, Shaywitz BA, Leckman JF, Anderson GM, Shaywitz SE, Hardin MT, Ort SI, Cohen DJ. Brief debrisoquin administration to assess central dopaminergic function in children. Life Sci. 1986 Mar 17;38(11):1041-8. doi: 10.1016/0024-3205(86)90239-0. PMID: 3456480.


4: Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989 Jan;45(1):72-9. doi: 10.1038/clpt.1989.11. PMID: 2910639.


5: Parker RB, McCollam PL, Bauman JL. Propafenone: a novel type Ic antiarrhythmic agent. DICP. 1989 Mar;23(3):196-202. doi: 10.1177/106002808902300301. PMID: 2655298.


6: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):159-84. PMID: 12087878.


7: Schultz FB. Clinical study of the antihypertensive effects of debrisoquin sulfate in combination with hydrochlorothiazide. J Med Assoc State Ala. 1966 Aug;36(2):147-53. PMID: 5329755.


8: Blechman M, Sokol C, Moser M. Debrisoquin sulfate: a clinical evaluation of a new antihypertensive agent. Curr Ther Res Clin Exp. 1969 Feb;11(2):71-6. PMID: 4975816.


9: Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL. The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x. PMID: 371651; PMCID: PMC1429493.


10: Riddle MA, Jatlow PI, Anderson GM, Cho SC, Hardin MT, Cohen DJ, Leckman JF. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Neuropsychopharmacology. 1989 Jun;2(2):123-9. doi: 10.1016/0893-133x(89)90015-8. PMID: 2742727.


11: Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634. PMID: 1981634.


12: LURIA MH, FREIS ED. TREATMENT OF HYPERTENSION WITH DEBRISOQUIN SULFATE (DECLINAX). Curr Ther Res Clin Exp. 1965 May;7:289-96. PMID: 14286208.


13: Steventon GB, Heafield MT, Sturman S, Waring RH, Williams AC. Xenobiotic metabolism in Alzheimer's disease. Neurology. 1990 Jul;40(7):1095-8. doi: 10.1212/wnl.40.7.1095. PMID: 2356011.


14: Biron P. Un nouvel antihypertenseur sympathoplégique: le sulfate de débrisoquine [New sympathoplegic antihypersensive agent: debrisoquin sulfate]. Union Med Can. 1973 May;102(5):1134-5. French. PMID: 4712043.


15: Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO. Polymorphic debrisoquin metabolism in a Turkish population. Clin Pharmacol Ther. 1994 Apr;55(4):399-401. doi: 10.1038/clpt.1994.48. PMID: 8162666.


16: Onesti G, LaSchiazza D, Brest AN, Moyer JH. Cardiac and renal hemodynamic effects of debrisoquin sulfate in hypertensive patients. Clin Pharmacol Ther. 1966 Jan-Feb;7(1):17-20. doi: 10.1002/cpt19667117. PMID: 5325582.


17: ABRAMS WB, POCELINKO R, KLAUSNER M, HANAUER L, WHITMAN EN. CLINICAL PHARMACOLOGICAL STUDIES WITH DEBRISOQUIN SULFATE, A NEW ANTIHYPERTENSIVE AGENT. J New Drugs. 1964 Sep-Oct;4(5):268-83. doi: 10.1002/j.1552-4604.1964.tb00372.x. PMID: 14218621.


18: Brøsen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol. 1989;37(2):155-60. doi: 10.1007/BF00558224. PMID: 2792169.


19: O'Brien BW. The management of essential hypertension. JAMA. 1974 Aug 5;229(6):693-4. PMID: 4408383.


20: Boudet C, Peyrin L, Tavitian E, Claustre J, Favre R. Studies on the central or peripheral origin of free and sulfated 3,4-dihydroxyphenylacetic acid in rat plasma. Eur J Pharmacol. 1984 Aug 17;103(3-4):295-301. doi: 10.1016/0014-2999(84)90490-4. PMID: 6149138.